Ranibizumab

Showing results 51 - 57 of 57

Sorted by most recent

TitleAuthorDate

Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept

Chikako Hara, Taku Wakabayashi, Hiroshi Toyama, Yoko Fukushima, Kaori Sayanagi, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida

15 June 2018

Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy

Manabu Miyata, Sotaro Ooto, Kenji Yamashiro, Hiroshi Tamura, Masayuki Hata, Naoko Ueda-Arakawa, Munemitsu Yoshikawa, Shogo Numa, Akitaka Tsujikawa

6 June 2018

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

Charles C Wykoff, William C Ou, Rahul N Khurana, David M Brown, W Lloyd Clark, David S Boyer

13 April 2018

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data

Aaron Y Lee, Thomas Butt, Emily Chew, Elvira Agron, Traci E Clemons, Catherine A Egan, Cecilia S Lee, Adnan Tufail

22 March 2018

Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial

Charles C Wykoff, William C Ou, Daniel E Croft, John F Payne, David M Brown, W Lloyd Clark, Nizar Saleh Abdelfattah, SriniVas R Sadda

22 March 2018

Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy

Shinichi Sakamoto, Hidenori Takahashi, Xue Tan, Yuji Inoue, Yoko Nomura, Yusuke Arai, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi

22 March 2018

Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema

Bianca S Gerendas, Sonja Prager, Gabor Deak, Christian Simader, Jan Lammer, Sebastian M Waldstein, Tadhg Guerin, Michael Kundi, Ursula Margarethe Schmidt-Erfurth

20 January 2018

Prev 1 2 3 4 56